Decreased sputum Caveolin-1 is associated with systemic sclerosis related lung disease

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 31, Issue 1, 2014, Pages 55-61

  Yilmaz, Neslihan ^a   Olgun, Sehnaz ^a   Ahiskali, Rengin ^a   Karakurt, Sait ^a   Yavuz, Sule ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Caveolin 1; Lung disease; Scleroderma

Indexed keywords

CAVEOLIN 1; ENDOTHELIN 1; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ALVEOLITIS FIBROSIS INDEX; ARTICLE; ASTHMA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY TRACT PARAMETERS; SPUTUM; SPUTUM ANALYSIS; SYSTEMIC SCLEROSIS; BLOOD; CASE CONTROL STUDY; CHEMISTRY; COMPLICATION; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; CASE-CONTROL STUDIES; CAVEOLIN 1; ENDOTHELIN-1; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SPUTUM; TRANSFORMING GROWTH FACTOR BETA;

EID: 84900529766     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Seibold JR. Scleroderma. In: Harris ED, Budd RC, eds. Kelley's textbook of Rheumatology. Volume II. Philadelphia, Elsevier. 2005;1279-1303
2. Silver RM, Clements PJ. Interstitial lung disease in systemic sclerosis: optimizing evaluation and management. Scleroderma care and research. 2003; 1:3-11
3. Ostojic P, Cerinic MM, Silver R, et al. Interstitial lung disease in systemic sclerosis. Lung. 2007; 185: 211-220 (Pubitemid 47101358)
4. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis 1972-2002. Ann. Rheum. Dis. 2007; 66: 940-944 (Pubitemid 46999798)
5. Flanders KC, Roberts AB. TGF beta. In: Feldman M, Oppenheim JJ. Cytokine Reference. Vol. 1. Academic Press. 2001;719-74.
6. Howe PH. Transforming growth factor β. In: Thomson AW, Lotze MT. The Cytokine Handbook. 4th ed. Academic Press. 2003;1119-1152.
7. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
8. Hyytiainen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci. 2004;4:233-264. (Pubitemid 38888060)
9. Ludwicka A, Ohba T, Trojanowska M, et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol.1995;22:1876-1883.
10. Tourkina E, Richard M, Gooz P, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2008;294:843-861.
11. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, TGF-β receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2008;20:713-719.
12. Wang XM, Zhang Y, Kim HP, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary Fibrosis. The Journal of Experimental Medicine. 2006;203:2895-2906 (Pubitemid 46026167)
13. Zhang XL, Topley N, Ito T, et al. Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J Biol Chem. 2005;280:12239-12245.
14. Di Guglielmo GM, Le Roy C, Goodfellow AF, et al. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol. 2003;5:410-421. (Pubitemid 36592263)
15. Razani B, Woodman SE, Lisanti MP. Caveolae: From Cell Biology to Animal Physiology. The American Society for Pharmacology and Experimental Therapeutics. 2002;54:3-8
16. Tourkina E, Gooz P, Pannu J, et al. Opposing effects of protein kinase C alpha and protein kinase C epsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J. Biol. Chem. 2005;280:13879-13887 (Pubitemid 40517287)
17. Bains SN, Tourkina E, Atkinson C, et al. Loss of caveolin-1 from bronchial epithelial cells ad monocytes in human subjects with asthma. Allergy. 2012; 67(12): 1601-1604
18. Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 1997;151:831-841. (Pubitemid 27385615)
19. Shi-Wen X, Kennedy L, Renzoni EA, et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum 2007;56:4189-4194. (Pubitemid 350262347)
20. Reichenberger F, Schauer J, Kellner K, et al. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung. 2001;179(3):163-174 (Pubitemid 34033112)
21. Yilmaz N, Abul Y, Bicakcigil M, et al. Induced sputum as a method for detection of systemic sclerosis related interstitial lung disease. Rheumatol Int 2011;32(7):1921-1925
22. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-205. (Pubitemid 18073738)
23. Goh NS, Desai SR, Veeraraqhavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Resp Crit Care Med. 2008; 177(11): 1248-1254 (Pubitemid 351860934)
24. Warrick JH, Bhalla M, Schabel SI, et al. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18:520-528
25. Bellia M, Cannizzaro F, Scichilone N, et al. HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities. Radiology med. 2009;114:190-203
26. Medsger TA, Silman AJ, Stehen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-2167 (Pubitemid 29487010)
27. Efthimiadis A, Spanevello A, Hamid Q, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl. 2002;37:19-23
28. Kasper M, Reimann T, Hempel U, et al. Loss of caveolin expression in type I pneumocytes as an indicator of subcellular alterations during lung fibrogenesis. Histochem Cell Biol. 1998;109:41-48. (Pubitemid 28085695)
29. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001;293:2449-2452. (Pubitemid 32917325)
30. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable, but show evidence of hyper-proliferative and vascular abnormalities. J Biol Chem. 2001;276:38121-38138.
31. De Galdo F, Sotgia F, Almeida C, et al. Decreased expression of caveolin-1 in Systemic Sclerosis; crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008; 58(9): 2854-2865
32. Tourkina E, Richard M, Oates J. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis. 2010;69:1220-1226
33. Manetti M, Allanore Y, Mohamad S, et al. Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. Ann Rheum Dis. 2012; 71:1034- 1041
34. Le Saux CJ, Teeters K, Miyasato SK, et al. Down-regulation of Caveolin-1, an inhibitor of transforming growth factor-beta signaling, in acute allergen-induced airway remodeling. The Journal of Biological Chemistry. 2008;283:5760-5768
35. Hashimoto S, Gon Y, Takeshita I, et al. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med. 2001;163:152-157 (Pubitemid 32095266)
36. Border WA, Noble NA. Targeting TGF-beta for treatment of disease. Nat Med. 1995;1:1000-1001
37. Kenyon NJ, Ward RW, McGrew G, et al. TGF-beta1 causes airway fibrosis and increased collagen I and III mRNA in mice. Thorax. 2003;58:772-777 (Pubitemid 37094053)
38. Dziadzio M, Smith RE, Abraham DJ, et al. Circulating levels of active transforming growth factor β1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology. 2005;44:1518-1524 (Pubitemid 41742468)
39. Scala E, Pallotta S, Frezzolini A, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004;138: 540-546 (Pubitemid 39573637)
40. Deguchi Y. Spontaneous increase of transforming growth factor beta production by bronchoalveolar mononuclear cells of patients with systemic autoimmune diseases affecting the lung. Annals of the Rheumatic Diseases. 1992;51:362-365
41. Ludwicka A, Ohba T, Trojanowska M, et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol. 1995;22:1876-1883.
42. Batra V, Musani AI, Hastie AT, et al. Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-beta1, TGF-beta2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. Clin Exp Allergy. 2004;34:437-444 (Pubitemid 38373007)
43. Redington AE, Madden J, Frew AJ, et al. Transforming growth factor-beta 1 in asthma. measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med. 1997;156:642-647 (Pubitemid 27352007)